Oncology Practice Management Realities
Oncology practice management is the most operationally complex of any ambulatory specialty. Drug cost dominates — chemotherapy, immunotherapy, and targeted agents can represent 60–75% of practice revenue flowing through on a buy-and-bill basis. Oral oncolytics shift economics toward specialty pharmacy. Treatment regimen safety, clinical trial enrollment, and complex multi-disciplinary coordination add operational layers. Medicare and commercial insurance mix varies but Medicare typically 50–65% per ASCO data.
Revenue Cycle Complexity
Revenue cycle is drug-cost-dominated. ASP (Average Sales Price) + 6% Medicare reimbursement model means margin is thin after acquisition cost — 340B program eligibility (for hospital-based and certain community practices) dramatically changes economics. Prior authorization is essentially universal and complex (NCCN pathway compliance, payer-specific protocols). Biosimilar substitution workflow is now standard. Part B drugs vs. Part D (oral oncolytics) have different coverage/billing paths. Clinical trial revenue (sponsor payments for enrollment, visit completion, milestone payments) adds separate revenue stream. No Surprises Act (CMS) compliance matters for OON pathology and radiology used in workup.
Operational Workflow
Operational workflow is infusion-center-centered. Chair capacity, nursing staffing, pharmacy compounding, and protocol adherence define throughput. Pre-medication, drug preparation (USP 797 clean room compliance for compounding), administration, monitoring, and post-infusion assessment each require structured time. Patient education, financial navigation, and nursing triage for toxicity management are staff-intensive. Clinical trial workflow adds eligibility screening, protocol documentation, regulatory compliance, and sponsor reporting. Oncology-specific social work (financial assistance, transportation, side-effect support) is often part of practice.
Regulatory & Industry Framework
What Changes at Scale
Scaling oncology creates substantial operational leverage. Mid-size groups (10-20 oncologists) benefit from dedicated financial navigation, in-house pharmacy compounding, and concentrated clinical trial participation. Large platforms (30+ oncologists) operate multiple infusion centers with shared drug purchasing, centralized prior auth, and data-driven pathway optimization. PE-backed oncology platforms (OneOncology, American Oncology Network) and physician-led networks (US Oncology) operate national-scale networks. Community vs. hospital-based oncology have fundamentally different economics given 340B.
Related Services & Specialties
Geographic Coverage
Practice management support across all 11 NJ counties: Bergen, Hudson, Essex, Passaic, Morris, Union, Middlesex, Monmouth, Somerset, Ocean, Mercer. Major cities: Hackensack, Newark, Jersey City, Paterson, Elizabeth, Morristown, New Brunswick, Princeton, Trenton, Toms River. See complete locations directory.
How an Engagement Starts
Our process is structured, documented, and starts with listening — not pitching.
Step 1 — Discovery call (30 minutes, no obligation). Practice owner or office manager. We listen. What's working, what's broken, what's the immediate pain point. No pitch, no vendor pressure, no slide deck.
Step 2 — Scoped assessment. On-site or remote — we inventory infrastructure, EHR environment, cybersecurity posture, vendor contracts, and clinical workflow patterns. Typically 2-5 business days depending on practice size. Deliverable: a written assessment with findings and prioritized remediation recommendations.
Step 3 — Proposal and engagement structure. If Oncology practice management is a fit, we propose an engagement — scope, pricing, timeline, measurable outcomes. No long-term lock-in contracts on first engagement. If we're not the right fit, we'll tell you directly.
Step 4 — Onboarding and delivery. Structured 30-60 day onboarding with clear milestones. Documentation, tooling deployment, knowledge transfer, and operational handoff. You know exactly what's happening and when.
For practices currently with a generalist MSP, see our Qventive vs. generalist MSP comparison. For practices evaluating internal hire vs. managed services, see managed IT vs. internal hire. For questions on the MSP landscape generally, our resources and FAQ pages cover common questions.
Why Qventive, Specifically
Not a pitch — a factual description of how we're structured differently.
Healthcare-exclusive since 1994. Every engineer, every helpdesk technician, every account manager works only with medical practices. No retail, no law firms, no logistics companies. That focus has operational consequences — our on-call engineer at 2 a.m. knows what a downtime toolkit is for Epic. Our helpdesk understands that “the EHR is slow” is an emergency, not a ticket.
Steve Gerbino founded this company in 1994. The founder still answers questions. The depth of specialty and clinical workflow knowledge compounded over three decades is genuinely hard to replicate — and it's why we serve solo practices, group practices, multi-location practices, FQHCs, ASCs, concierge medicine, hospital-adjacent practices, and PE-backed platforms with equal depth.
Observe-Improve-Prevent methodology. Every engagement starts with observation — shadowing providers, auditing infrastructure, reviewing documentation. We don't assume. Then we improve based on what we actually see. Then we monitor continuously to prevent drift. This isn't a marketing slogan — it's an operational pattern baked into how our engineers work.
Geographic proximity. Our Bergen County headquarters in Hackensack means fast on-site response across NJ. We're not a 50-state remote-only MSP. When something needs hands-on work — new infrastructure, physical troubleshooting, device deployment — we send people. Learn more about us, our why Qventive positioning, and read testimonials from practices we serve.
Frequently Asked Questions
Detailed answers from 30+ years of healthcare-exclusive IT and practice management expertise.
How does buy-and-bill economics work?+
Practice purchases chemotherapy at acquisition cost, administers to patient, bills insurance (Medicare Part B: ASP + 6% before sequester; commercial: varies). Margin is narrow. Drug cost often 60-75% of oncology revenue. 340B-eligible practices get drug at discounted cost (up to 50%+ below standard), creating dramatically different economics vs. community oncology.
What about biosimilar substitution?+
Biosimilars for Herceptin (trastuzumab), Rituxan (rituximab), Avastin (bevacizumab), Neulasta (pegfilgrastim), Neupogen (filgrastim) are standard. Interchangeability varies by product. Practice workflow: payer preference checking, biosimilar-appropriate prior auth, patient education, switching workflow, outcome monitoring. Margin impact: biosimilar ASP+6% is lower than originator, but acquisition cost is also lower.
How do you handle oral oncolytic specialty pharmacy?+
Oral oncolytics (TKIs, hormone therapy, some immunotherapies) flow through specialty pharmacy (Medicare Part D or commercial specialty pharmacy benefit). Different from Part B buy-and-bill. Practice loses the drug revenue but also eliminates inventory/compounding burden. Prior auth still extensive. Adherence monitoring matters.
What's CMMI EOM?+
Enhancing Oncology Model (successor to OCM). Value-based oncology model — 5-year program. Monthly Enhanced Oncology Services payment for navigation, plus shared savings/risk on total cost of care. Specific quality measures, Patient Navigator role requirement, 24/7 availability requirement, health-related social needs screening. Participating practices need workflow adaptations.
How do you handle clinical trials operationally?+
Clinical trial workflow: sponsor relationships (pharma, academic, cooperative groups), feasibility assessment, IRB management, eligibility screening at clinic, protocol-specific scheduling, sponsor reporting, milestone billing. CTMS (Clinical Trial Management System) platforms (Oncore, Veeva). Trial revenue covers research staff, sometimes physician time.
What about financial navigation?+
Cancer treatment cost-sharing drives patient financial toxicity. Dedicated financial navigators help patients access manufacturer assistance programs, foundation grants, copay assistance, pharmaceutical patient assistance. Reduces patient dropout rates. Multi-FTE role in any reasonable-sized practice.
How do you handle QOPI MIPS reporting?+
QOPI (Quality Oncology Practice Initiative) is ASCO's QCDR. Oncology-specific measures (pain management, end-of-life care, chemotherapy safety, survivorship care plans). MIPS submission through QOPI. QOPI Certification is separate program (practice-level quality certification).
How does PE change oncology PM?+
PE platforms scale drug purchasing (platform-wide contracts), centralize prior auth, consolidate clinical trial networks, deploy platform-wide pathway software, unified reporting. See PE page.
Does Qventive serve my area?+
Last Updated: April 2026 · Reviewed by Qventive Healthcare clinical technology team
